Dr Philip Supply, Director of Research at the CNRS and Scientific Adviser at GenoScreen, has received the prestigious Gardner Middlebrook Lifetime Achievement Award at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) on 26 June 2022 in Bologna – Italy.
Bureau Veritas Certification has renewed GenoScreen’s ISO 9001:2015 and ISO 13485:2016 certifications for 3 years, demonstrating our continuous commitment to quality and efforts to satisfy our customers as best as possible, in compliance with legal and regulatory requirements.
Adebiotech is organising a new day dedicated to innovative approaches in the fight against antibiotic resistance. The event will take place on September 16, 2021 at the Genopôle (Campus 1) in Evry-Courcouronnes – FRANCE. Conferences will address preventive actions (microbiota, immunomodulation, new vaccines…), innovations in diagnostics (AI and Big data,...
Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a...
The innovative Deeplex® Myc-TB test for antibiotic resistance prediction in tuberculosis, created by GenoScreen, has been evaluated by an Indian research team. By testing approximately 40 clinical samples, this study validates the use of Deeplex® Myc-TB, by demonstrating its usability in hospital environments. These results confirm the interest of its...
